Literature DB >> 2689041

Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part II).

P Veng-Pedersen1.   

Abstract

Part I of this article, which appeared in the previous issue of the Journal, covered the following topics: fundamental definitions, general mean time parameter relationships and mean time parameters of classical compartmental systems. It also offered a number of examples to clarify and illustrate the various concepts.

Mesh：

Year:  1989        PMID： 2689041     DOI： 10.2165/00003088-198917060-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


  83 in total

1.  Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.

Authors:  P V Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

2.  Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients.

Authors:  R A Herman; P Veng-Pedersen; J Hoffman; R Koehnke; D E Furst
Journal:  J Pharm Sci       Date:  1989-02       Impact factor: 3.534

3.  A method for evaluating the mean residence times of metabolites in the body, systemic circulation, and the peripheral tissue not requiring separate i.v. administration of metabolite.

Authors:  P Veng-Pedersen; W R Gillespie
Journal:  Biopharm Drug Dispos       Date:  1987 Jul-Aug       Impact factor: 1.627

4.  A linear recirculation model for drug disposition.

Authors:  D J Cutler
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

5.  A polyexponential deconvolution method. Evaluation of the "gastrointestinal bioavailability" and mean in vivo dissolution time of some ibuprofen dosage forms.

Authors:  W R Gillespie; P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1985-06

6.  Model-independent assessment of accumulation kinetics based on moments of drug disposition curves.

Authors:  M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Comments on mean residence time determination.

Authors:  E M Landaw; D Katz
Journal:  J Pharmacokinet Biopharm       Date:  1985-10

8.  Hemodynamic influences upon the variance of disposition residence time distribution of drugs.

Authors:  M Weiss
Journal:  J Pharmacokinet Biopharm       Date:  1983-02

9.  Moment analysis for the separation of mean in vivo disintegration, dissolution, absorption, and disposition time of ampicillin products.

Authors:  Y Tanigawara; K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharm Sci       Date:  1982-10       Impact factor: 3.534

10.  Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function.

Authors:  J T Burke; W A Wargin; R J Sherertz; K L Sanders; M R Blum; F A Sarubbi
Journal:  J Pharmacokinet Biopharm       Date:  1982-12
View more
  18 in total

1.  Bias and variance of extrapolated tails for area-under-the-curve (AUC) and area-under-the-moment-curve (AUMC).

Authors:  R D Purves
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography.

Authors:  David L Chin; Bert L Lum; Branimir I Sikic
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-11-05       Impact factor: 3.205

3.  Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients.

Authors:  T J Wilkinson; B A Robinson; E J Begg; S B Duffull; P J Ravenscroft; J J Schneider
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Optimum numerical integration methods for estimation of area-under-the-curve (AUC) and area-under-the-moment-curve (AUMC).

Authors:  R D Purves
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

5.  Optimal extravascular dosing intervals.

Authors:  P Veng-Pedersen; N B Modi
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

6.  Accuracy of noncompartmental pharmacokinetic parameters estimated from bolus injection and steady-state infusion data.

Authors:  M Looby; M Weiss
Journal:  J Pharmacokinet Biopharm       Date:  1995-12

7.  Effect of polyaspartic acid on pharmacokinetics of gentamicin after single intravenous dose in the dog.

Authors:  T Whittem; K Parton; K Turner
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

8.  Assessment of exposure to PCB 153 from breast feeding and normal food intake in individual children using a system approach model.

Authors:  Tomáš Trnovec; Ladislav Dedík; Todd A Jusko; Kinga Lancz; Lubica Palkovičová; Anton Kočan; Eva Šovčíková; Soňa Wimmerová; Juraj Tihányi; Henrieta Patayová; Irva Hertz-Picciotto
Journal:  Chemosphere       Date:  2011-11-01       Impact factor: 7.086

9.  Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin.

Authors:  Peter Veng-Pedersen; Kevin J Freise; Robert L Schmidt; John A Widness
Journal:  J Pharm Pharmacol       Date:  2008-10       Impact factor: 3.765

10.  The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients.

Authors:  J Sahai; K Gallicano; G Garber; I McGilveray; N Hawley-Foss; N Turgeon; D W Cameron
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.